Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferring receptor
1997
Targeting Doxorubicin Resistance in Leukemia Cells
publication
Evidence: moderate
Author Information
Author(s): S Suzuki, K Inoue, A Hongoh, Y Hashimoto, Y Yamazoe
Primary Institution: Tohoku University
Hypothesis
Can immunoliposomes targeting transferrin receptors overcome doxorubicin resistance in leukemia cells?
Conclusion
The study found that immunoliposomes can effectively increase doxorubicin sensitivity in doxorubicin-resistant leukemia cells.
Supporting Evidence
- OKT9-CIL showed similar binding to both K562 and K562/ADM cells.
- After treatment with OKT9-CIL, the difference in sensitivity to doxorubicin between K562 and K562/ADM was diminished.
- DOX levels in K562/ADM after OKT9-CIL treatment were nearly equivalent to those in K562.
Takeaway
Researchers created special liposomes that can help a cancer drug work better in resistant leukemia cells.
Methodology
The study used doxorubicin-resistant K562/ADM leukemia cells and tested the effects of immunoliposomes on drug sensitivity and internalization.
Want to read the original?
Access the complete publication on the publisher's website